FISH: NTRK1/2/3 GENE REARRANGEMENT ASSAY

NEUROTROPHIC TROPOMYOSIN RECEPTOR KINASE (NTRK) GENE REARRANGEMENTS HAVE RECENTLY EMERGED AS TARGETS FOR CANCER THERAPY. GENE REARRANGEMENTS THAT INVOLVE NTRK1/2/3 CAN GENERATE FUSION ONCOPROTEINS THAT CONTAIN THE KINASE DOMAINS OF TRKA/B/C, RESPECTIVELY. IN NSCLC (NON SMALL CELL LUNG CANCER), NTRK FUSIONS ARE ESTIMATED TO OCCUR AT A FREQUENCY OF APPROXIMATELY 0.1% TO 1%. THE TRK INHIBITORS NAMELY, LAROTRECTINIB (LOXO-101) AND ENTRECTINIB (RXDX-101) ARE ORAL TYROSINE KINASE INHIBITORS THAT HAVE HIGH SELECTIVITY AND POTENCY FOR TRKA, TRKB, AND TRKC. THIS PANEL PROVIDES SIMULTANEOUS ANALYSIS OF NTRK1/2/3 GENE REARRANGEMENTS TO IDENTIFY TRK-INHIBITOR THERAPY IN SOLID TUMORS.